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Peripheral blood dendritic cells and GM-CSF as an adjuvant
for hepatitis B vaccination in hemodialysis patients.
Background. Dysfunctional antigen presentation may under-
lie the impaired antibody response to hepatitis B vaccination
in hemodialysis patients. Dendritic cells are considered to be
the most important antigen presenting cells, but their presence
and function in hemodialysis patients is unclear. Granulocyte-
monocyte-colony stimulating factor (GM-CSF) has been given
successfully to hemodialysis patients to increase the proportion
of responders to hepatitis B vaccination. Although GM-CSF
acts on both monocytes and dendritic cells, the mechanisms un-
derlying its adjuvant quality are largely unknown.
Methods. In this study we analyzed monocytes and dendritic
cells in the peripheral blood of hemodialysis patient that had
responded to a standard hepatitis B vaccination procedure (re-
sponders), patients who had not responded (nonresponders),
and healthy controls. The nonresponders were given two ad-
ditional booster vaccines, both preceded by administration of
GM-CSF the day before.
Results. After two booster vaccinations with GM-CSF, six
out of seven patients developed a protective antibody response
to hepatitis B. The memory T-cell response to tetanus toxoid
was significantly lower in nonresponders compared to controls.
The monocytes of dialysis patients and healthy controls showed
a similar expression of relevant cell surface molecules. How-
ever, the numbers of circulating dendritic cells were on average
50% reduced compared to healthy controls, with a further re-
duction after GM-CSF administration. This was accompanied
by a decrease of T-cell proliferation in antigen presentation
assays. Monocytes showed increased major histocompatibility
complex (MHC) class II, CD54, and CD40 expression, while
their antigen-presenting capacity remained unchanged.
Conclusion. GM-CSF is an effective adjuvant for hepatitis
B vaccination in primary nonresponding hemodialysis patients,
but paradoxically decreases the antigen presenting capacity of
peripheral blood mononuclear cells and the number of circu-
lating dendritic cells.
Key words: dendritic cells, dialysis, vaccination, GM-CSF, hepatitis B.
Received for publication November 3, 2003
and in revised form December 19, 2003, and January 29, 2004
Accepted for publication February 20, 2004
C© 2004 by the International Society of Nephrology
The impaired immune response after hepatitis B vac-
cination is a long-standing problem in dialysis patients
and is commonly viewed as a symptom of a more
generalized impaired immune system in patients with
end-stage renal disease (ESRD) [1, 2]. The mechanisms
underlying this phenomenon are incompletely under-
stood, although many changes in both immunophenotype
and function of monocytes and T cells have been docu-
mented in these patients. As early as the late eighties, it
was shown that patients that did not respond to a standard
hepatitis B vaccination procedure (primary nonrespon-
ders) showed a decreased T-cell proliferation after stim-
ulation by monoclonal antibodies directed against CD3.
Monocytes of dialysis patients appeared to be relative in-
effective antigen presenting cells resulting in decreased
interleukin (IL)-2 production by T cells after stimu-
lation. [3]. The T-cell proliferation response could be
restored by coculture with transfected fibroblasts ex-
pressing the important costimulatory molecule B7, which
is normally expressed by antigen presenting cells [4].
Later, Girndt et al [5] reported a small decrease in ex-
pression of the B7-2 (CD86) molecule on monocytes of
patients on hemodialysis compared to healthy controls.
Although peripheral blood T cells from patients with
ESRD show signs of activation, they have a normal prolif-
eration capacity after stimulation with cytokines or het-
erologous monocytes [1, 6, 7]. Based on these findings,
the conclusion has been drawn that decreased antigen-
presenting capacity of monocytes may underlie the de-
creased vaccination response in hemodialysis patients.
However, dendritic cells and not monocytes are con-
sidered to be the most potent antigen-presenting cell ca-
pable of inducing a primary immune response. In the skin
they are present as Langerhans cells and dermal dendritic
cells that can efficiently take up and process antigen, and
thereafter migrate to the draining lymph node for anti-
gen presentation to antigen-specific T cells [8, 9]. This
normal physiology of antigen presentation can be very
effectively reproduced by subcutaneous vaccination with
in vitro antigen-loaded monocyte-derived dendritic cells
[10].
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Dendritic cells also circulate at low frequency in the
peripheral blood before migrating to lymphoid tissues,
skin, and organs [9, 11]. They can be differentiated in a
myeloid type called DC1 and a lymphoid type DC2, which
have different functional characteristics that may result
in either preferential T-helper 1 or 2 stimulation [12]. No
data are available about the presence and function of
circulating dendritic cells in patients with chronic renal
failure.
Granulocyte-monocyte-colony-stimulating factor (GM-
CSF) is a specific growth factor for hematopoietic pro-
genitor cells and promotes their differentiation into
granulocytes, monocytes and dendritic cells. Administra-
tion in vivo leads predominantly to granulocytosis and
influences phagocytosis, cytotoxicity, and cytokine pro-
duction of monocytes and granulocytes [13, 14]. GM-CSF
is now being recognized as a potential effective adju-
vant in many different vaccination procedures [15]. A
recent randomized controlled study showed that after an
optimal dose of GM-CSF, given before hepatitis B vac-
cination, all hemodialysis patients developed protective
antibody titers [16]. However, the mechanisms underly-
ing the potency of GM-CSF as adjuvant are largely un-
known [17].
In the present study we analyzed the phenotype
and function of circulating antigen-presenting cells in
hemodialysis patients compared to healthy controls, and
after administration of GM-CSF.
METHODS
Sixteen patients on chronic intermittent hemodialysis
were analyzed. No patient was suffering from a malig-
nancy or autoimmune disease, or was taking immuno-
suppressive medication. All patients had undergone a
hepatitis B vaccination program consisting of four in-
tramuscular injections of 40 lg of hepatitis B vaccine
(HB-VAX) (APMSD, Brussels, Belgium) at time 0, 1, 6,
and 12 months. Eight patients were considered primary
nonresponders as their antibody response to hepatitis B
surface antigen (HbsAg) remained below 10 IU/mL
(two patients below 2 IU/mL and six patients below
0.1 IU/mL). Normally, no additional boosters are given
because in our patient population this does not result
in an increased number of vaccination responders. The
nonresponders in this study were given two additional
intramuscular injections of 40 lg HB-VAX at 1-month
intervals in the deltoid region. HB-VAX was always ad-
ministered on the day of a dialysis session. Twenty-four
hours before each of these boosters, GM-CSF (Leuco-
max; Novartis, Arnhern, The Netherlands) at 3 lg/kg was
given subcutaneous. Serum antibody titers for hepatitis B
surface antigen were measured before and 1 month after
the booster injections.
All patients were in stable clinical condition before and
during the study period. They were dialyzed three times
weekly for 4 hours. All patients were dialyzed with hemo-
phane (MA-12H) (Kawasumi Laboratory Inc., Tokyo,
Japan) dialyzer membranes. Healthy nursing staff and
laboratory personnel were the control population.
The local medical ethical committee approved the
study and informed consent was obtained from every
patient.
Sample preparation
Blood samples were collected in pyrogen-free tubes
containing heparin. Blood drawn from hemodialysis pa-
tients was always taken before the start of the hemodial-
ysis procedure. On every blood sample a differential
cell count was done. Peripheral blood mononuclear cells
(PBMC) were isolated layering the blood on a Ficoll-
Paque gradient (Amersham Pharmacia Biotech, Upp-
sala, Sweden). After centrifugation, the PBMC were
removed from the interface and washed several times
with ice-cold phosphate-buffered saline (PBS) to remove
the platelets.
Monocytes were purified from the PBMC by labeling
them with anti-CD14–coated magnetic beads. Monocytes
were purified by positive selection using MACS CD14
isolation kit (Milteny Biotec, Bergisch, Gladbach, Ger-
many) on an AutoMACS (Milteny Biotec) according to
the manufacturer’s protocol. This yielded a monocyte
population of greater then 98% purity with no detectable
dendritic cells present.
Flow cytometric analysis
Whole blood samples were monitored for the ex-
pression of cell surface markers on monocytes. Two-
color flow cytometry was used after staining with
CD14 (phycoerytrin-labeled) as a marker for monocytes
in combination with antibodies directly conjugated to
fluorescein isothiocyanate (FITC), to detect major his-
tocompatibility complex (MHC) expression (anti-MHC
class I and II), adhesion molecules (CD58, CD54, and
CD102) and costimulatory molecules (CD40, CD80, and
CD86).
Dendritic cells were identified as human leukocyte
antigen (HLA)-DR–positive (PerCP-labeled antibody),
lineage negative cells (negative for CD3, CD19, CD20,
CD16, CD56, CD14, and CD34, all labeled with FITC).
DC1 were identified as CD11c (antigen-presenting cells–
labeled)-positive and DC2 were identified as CD123
(phycoerytrin-labeled)-positive and CD11c (antigen-
presenting cells–labeled)-negative. All antibodies were
purchased from Becton Dickinson (Mountain View, CA,
USA). The staining procedure was performed by incu-
bating 100 lL of blood with the optimal concentration of
antibody for 30 minutes at room temperature, followed
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by 10 minutes incubation with fluorescence-activated cell
sorter (FACS) lysing solution to lyse red blood cells. Sam-
ples were washed twice and flow cytometric analysis was
performed on a FACScalibur flow cytometer using Cell
Questpro software (Becton Dickinson).
The fluorescence intensity was measured in a semi-
quantative way to compare the measurements in time
[18]. In short, the flowcytometer was calibrated with
specific calibration beads in the range of 500 to 50,000
molecular equivalent of soluble fluorochrome (MESF)
(Calibration Beads Quantum 1000, RPE medium level)
(Bangs Labs Inc., Fishers, IN, USA). The intensity of the
fluorescence is converted to a standard curve using Quick
Cal program for Quantum Beads (Bangs Lab Inc.). The
geomean fluorescence level is denoted as MESF.
In vitro stimulation assays
In all stimulation assays the culture medium was RPMI
1640 (Gibco, Invitrogen Corp., Paisly, Scotland) supple-
mented with 2 mmol/L glutamine, 100 IU/L penicillin,
100 lg/L streptomycin, and 10% heat-inactivated human
AB serum. The allogeneic mixed leukocyte reaction (allo-
MLR) was used to test the capacity of PBMC to initiate a
primary immune response. Fifty thousand PBMC of the
patient were irradiated (30 Gy) and added to 50,000 al-
logeneic responder PBMC per well of a 96-wells round
bottom plate. After 7 days of incubation at 37◦C in a hu-
midified atmosphere containing 5% CO2, [3H]-thymidine
(0.5 lCi/well) was added for the last 8 hours of cul-
ture. Cells were harvested on a Tomtec 96-well and ra-
dioactivity was measured using a 1450 micro-Beta-Trilux
counter (Wallac, Turku, Finland). Results were expressed
as mean counts per minute. All experiments were done in
triplicate.
Allogeneic responder PBMC were harvested from
buffy coats obtained from the local blood bank and kept
at −140◦C until use. Every patient’s PBMC sample was
tested against PBMC from four different buffy coats.
Data are expressed as the mean counts per minute of
the four different buffy coats tested.
In a recall antigen proliferation assay the response
to nominal antigens like tetanus toxoid and Candida
albicans was tested. Fifty thousand PBMC in 200 lL
of control medium per well of a 96-wells round bot-
tom plate were tested by adding tetanus toxoid (RIVM,
Bilthoven, The Netherlands) or C. albicans (Artu Bio-
logicals, Lelystad, The Netherlands) in a final concentra-
tion of 37.5 limit of flocculation (Lf)/mL and 5 lg/mL.
After 7 days of incubation at 37◦C in a humidified atmo-
sphere containing 5% CO2, [3H]-thymidine (0.5 lCi/well)
was added for the last 8 hours of culture. Cells were
then harvested and radioactivity counted as counts per
minute. All experiments were performed in triplicate. As
a positive control the proliferation capacity of PBMC was
tested with phytohemagglutinin M (PHA-HA16) (Murex
Biotech Ltd, Dartford, Kent, UK) at a final concentration
of 2 lg/mL added to 50,000 cells per well in a 96-wells
round bottom plate.
In all proliferation experiments the PBMC alone
showed a background of less than 500 counts per minute.
Statistical analysis
Data obtained at every sample time-point are ex-
pressed as means with standard error of the mean. Statis-
tical analysis was performed using the Wilcoxon test for
paired observations, analysis of variance (ANOVA), and
the Pearson rank correlation test. Results were consid-
ered statistically significant when the P value was below
0.05. For multiple comparisons the Bonferroni correction
was applied on the P value (0.05/number of groups).
RESULTS
GM-CSF administration and hepatitis B
vaccination response
After the first booster of hepatitis B vaccine with GM-
CSF, seven out of eight patients developed a measurable
antibody titer, but only two patients showed a protec-
tive titer of greater then 10 IU/mL. The non-responding
patient subsequently did not want to participate in the
study anymore. After the second booster six out of seven
patients showed a protective antibody titer against hep-
atitis B surface antigen (average 144 IU/mL, range 11 to
480 IU/mL). The GM-CSF administration was well tol-
erated and no side effects were reported. However one
patient had an asymptomatic rise in body temperature
up to 38.8◦C (detected by routine body temperature mea-
surement before starting dialysis), the day after GM-CSF
administration on both occasions.
Cellular composition of peripheral blood leukocytes
The total number of white blood cells per mL periph-
eral blood was similar in all groups (Table 1). A rela-
tive lymphopenia in hemodialysis patients compared to
healthy controls was observed, which has been docu-
mented before [1, 18]. The proportions and absolute num-
bers of dendritic cells were substantially lower in patients
on hemodialysis compared to healthy controls. This was
observed for both DC1 and DC2 and to a similar degree
in both primary responders and nonresponders.
Twenty-four hours after administration of GM-CSF the
total number of white blood cells had increased, which
was fully accounted for by the increase in number of cir-
culating granulocytes. In all patients the percentage of
dendritic cells decreased dramatically resulting in a de-
crease in total numbers of DC1 and DC2 (Table 1) while
the numbers of monocytes remained stable.
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Table 1. Differential cell count of peripheral blood leukocytes of healthy controls and hemodialysis patients, which are responders or
nonresponders to standard hepatitis B vaccination
Controls Responders Nonresponders Nonresponders
(N = 8) (N = 8) (N = 8) after GM-CSFa
Leukocyte count × 106/mL 6.4 ± 1.5b 4.8 ± 1.5 5.8 ± 1.6 10.7 ± 1.9c
Granulocytes % 71.0 ± 7.2 79.0 ± 7.2 73.8 ± 8.8 85.2 ± 5.9c
Cell number × 106/mL 4.6 ± 1.2 3.8 ± 1.5 4.3 ± 1.3 9.1 ± 1.3c
Lymphocytes % 21.7 ± 5.9d 15.3 ± 7.1 15.5 ± 8.5 8.3 ± 3.6
Cell number × 105/mL 14.3 ± 7.0d 6.7 ± 2.4 8.8 ± 5.6 8.9 ± 4.3
Monocytes % 6.3 ± 3.7 6.3 ± 2.6 7.1 ± 4.3 9.6 ± 6.3
Cell number × 105/mL 4.3 ± 3.2 2.9 ± 1.3 6.2 ± 4.3 6.4 ± 4.3
Dendritic cells % 0.35 ± 0.96d 0.26 ± 0.13 0.20 ± 0.11 0.06 ± 0.02c
Cell number × 103/mL 23 ± 22d 11 ± 5 11 ± 8 7 ± 2.8c
DC1
Cell number × 103/mL 15 ± 8d 8 ± 4 8 ± 6.6 4 ± 2c
DC2
Cell number × 103/mL 6 ± 3.8d 3 ± 1.5 3 ± 1.8 2 ± 1c
GM-CSF is granulocyte-monocyte-colony-stimulating factor.
aPeripheral blood leukocytes obtained 24-hours after subcutaneous administration of GM-CSF to nonresponders. bData are expressed in means with standard error.
P values after Bonferroni correction for multiple comparisons were considered significant when below 0.015.
cP value <0.01 comparing data from nonresponders before and 24 hours after administration of GM-CSF.
dP value <0.01 comparing data from controls with responders and nonresponders.
Cell surface markers of monocytes
The cell surface markers of monocytes are shown in
Table 2. No statistical significant differences were ob-
served for the expression of these markers between
healthy controls and dialysis patients, nor between
responders or nonresponders to standard hepatitis B vac-
cination (data not shown). Twenty-four hours after ad-
ministration of GM-CSF major changes were observed.
The percentage of MHC class II expressing monocytes
increased and was accompanied by an at least fivefold
increase in the number of MHC class II molecules per
monocyte (expressed semiquantatively as MESF score).
Of the adhesion molecules only the cell surface expres-
sion of CD54 on monocytes increased significantly. Anal-
ysis of the expression of the costimulatory molecules
showed that the percentage of CD40-positive monocytes
increased (but not the MESF) while the percentage of
CD86 bearing monocytes decreased slightly.
Antigen presentation assays
Proliferation of memory T lymphocytes on recall
antigens like tetanus toxoid and C. albicans is de-
pendent on effective antigen presentation. Peripheral
blood mononuclear cells of the nonresponders in general
showed a lower proliferation on C. albicans antigen and
tetanus toxoid, compared to responders and healthy con-
trols (Fig. 1). In fact, only three out of eight patients in the
nonresponders group had a positive response on tetanus
toxoid, which was significantly different from healthy
controls.
The results of the allo-MLR showed similar prolifer-
ation responses in healthy controls and dialysis patients
(Fig. 2).
The day after GM-CSF administration, the T-cell pro-
liferation on tetanus toxoid and C. albicans antigen de-
Table 2. Expression of cell surface markers on monocytes of primary
nonresponders (N = 8) before and 24-hours after
granulocyte-monocyte-colony-stimulating factor (GM-CSF)
administration
Before GM-CSF After GM-CSF P valuea
MHC class I
% 100b 100
MESF 29411 ± 15917 23226 ± 14224 NS
MHC class II
% 83.2 ± 18.8 92.3 ± 6.8 0.05
MESF 7386 ± 5441 38590 ± 14617 0.0001
CD40
% 35.1 ± 17.8 63.5 ± 15.9 0.0002
MESF 1974 ± 2139 2379 ± 941 NS
CD54
% 67.3 ± 22.0 91.6 ± 5.5 0.005
MESF 1857 ± 965 5227 ± 2530 0.004
CD58
% 88.8 ± 23.5 96.8 ± 7.9 NS
MESF 2616 ± 1221 3487 ± 1514 NS
CD80
% 2.8 ± 1.9 6.1 ± 3.9 NS
MESF <500 <500
CD86
% 99.0 ± 1.9 94.3 ± 4.7 0.03
MESF 8140 ± 3310 4342 ± 3627 NS
CD102
% 100 100
MESF 23202 ± 7016 22501 ± 8065 NS
Abbreviations are: MHC, major histocompatibility complex; MESF, molecular
equivalent of soluble fluorochrome.
aThe P values are given for the statistical analysis of the difference in marker
expression before and after GM-CSF administration.
bData are expressed as percentage positive cells and MESF in means with
standard deviation.
creased substantial in the majority of patients. A similar
decrease in proliferation response was observed in the
allo-MLR (Fig. 2). Two patients showed an increase in
these responses (one patient in both allo-MLR and Can-
dida antigen assay and on patient only in the Candida
antigen assay), but we could not identify a relation with
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Fig. 1. Proliferation response of peripheral blood mononuclear cells
(PBMC) to the recall antigens tetanus toxoid and Candida albicans.
Data are expressed in counts per minute (CPM). PBMC of eight healthy
controls, eight hemodialysis patients who have responded to standard
hepatitis B vaccination (R), and eight patients who have not responded
(NR) were tested. The PBMC of the nonresponders were tested again
24 hours after subcutaneous administration of granulocyte-monocyte-
colony-stimulating factor (GM-CSF). The dotted horizontal line indi-
cates the lower limit of counts per minute above which responses are
considered positive (average counts per minute of negative control plus
three times the standard deviation). P values after Bonferroni correc-
tion for multiple comparisons were considered significant when below
0.015.
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Fig. 2. Proliferative response of allogeneic T cells from buffy coats
to peripheral blood mononuclear cells (PBMC). Data are expressed
in counts per minute (CPM). PBMC of eight healthy controls, eight
hemodialysis patients who have responded to standard hepatitis B vac-
cination (R), and eight patients who have not responded (NR) were
tested. The PBMC of the nonresponders were tested again 24 hours
after subcutaneous administration of granulocyte-monocyte-colony-
stimulating factor (GM-CSF). Buffy coats or PBMC alone (negative
controls) always showed a proliferative response less then 200 counts
per minute. P values after Bonferroni correction for multiple compar-
isons were considered significant when below 0.015.
number of dendritic cells or cell surface expression of
costimulatory molecules.
The number of dendritic cells in the peripheral blood
of dialysis patients showed a weak but significant relation
(P = 0.05, r = 0.42) with the proliferation responses in
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Fig. 3. Relation between number of dendritic cells in the peripheral
blood of hemodialysis patients and proliferation response of allogeneic
T cells in response to unfractionated peripheral blood mononuclear cells
(PBMC) from these patients. Data are shown from eight responder (•)
and eight nonresponders (◦) to hepatitis B vaccination. Statistical anal-
ysis was performed with the Pearson-rank correlation test and showed
a P value of 0.05. DC is dendritic cells.
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Fig. 4. Proliferation response in counts per minute (CPM) of allo-
geneic T cells (50,000 cells) to purified monocytes in graded doses
before (•) and after granulocyte-monocyte-colony-stimulating factor
(GM-GSF) administration (). Data are expressed as the means of the
results obtained with the monocytes from three different hemodialysis
patients. The results were similar when the experiment was repeated
using allogeneic T cells from a different buffy coat (data not shown).
the allo-MLR (Fig. 3). Such a relation could not be found
for monocytes.
Monocytes from the PMBC were purified to dissect
the relative role of monocytes versus dendritic cells as
antigen-presenting cells. Of three patients the monocytes
were isolated by positive selection on CD14 expression
yielding a highly purified population of monocytes with
no detectable dendritic cells present. These monocyte
populations were tested for their antigen presenting ca-
pacity in the allo-MLR using graded numbers of mono-
cytes (Fig. 4). The proliferation response of allogeneic
T cells was 10 to 20 times lower with isolated monocytes as
antigen-presenting cells then with unfractionated PBMC
containing dendritic cells. These responses did not change
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when either monocytes before or 24 hours after GM-CSF
administration were used.
DISCUSSION
In the present study we used subcutaneous GM-CSF
administration as an intervention in the immune system
of dialysis patients to potentiate the antibody response to
hepatitis B vaccination. In addition the effect of GM-CSF
on monocytes and dendritic cells, the two major popula-
tions of antigen-presenting cells in the peripheral blood
compartment, was analyzed. Confirming the data by oth-
ers, we showed the efficacy of GM-CSF as an adjuvant
for hepatitis B vaccination even in a group of primary
nonresponders [16]. The effect of GM-CSF is likely sys-
temic, since it was administered subcutaneously some
centimeters from the subsequent intramuscular admin-
istered hepatitis B vaccine. The systemic response was
also evident since all patients responded with peripheral
blood granulocytosis, a decrease in circulating numbers
of dendritic cells, and a changed immunophenotype of
the monocytes.
There is a paucity of studies documenting the effect
of GM-CSF on antigen presentation by monocytes. Re-
cently it was shown that in vitro exposure of human mono-
cytes to GM-CSF for 24 to 48 hours up-regulated the
expression of MHC class II, CD40 and marginally CD86
[17]. Prolonged exposure of monocytes to GM-CSF in
vitro lead to differentiation into macrophages [19]. Our
data are in accordance with the in vitro effects of GM-CSF
on monocytes. The day after GM-CSF administration,
peripheral blood monocytes of dialysis patients showed
both a major increase in MHC class II expression, as well
as an increase in the percentage of CD40-positive mono-
cytes. However, unlike the in vitro data, the CD86 cell
surface expression on circulating monocytes decreased
marginally.
Remarkably, the function of monocytes as stimulators
of allogeneic T cells did not change after subcutaneous
administration of GM-CSF, despite the major increase in
MHC class II expression. Monocytes exposed in vitro to
GM-CSF for 24 hours modestly increased their stimula-
tory capacity for allogeneic T cells, an effect observed
only at low monocyte to T-cell ratios [17]. Monocytes
are relative poor stimulators of naı¨ve and allogeneic
T cells, which at least partly can be contributed to their
low expression of co-stimulatory molecules like CD40
and CD86 [8, 20]. In vivo exposure to GM-CSF for
24 hours did not result in a major increase in monocyte
surface expression of these molecules, which may explain
the unchanged stimulatory capacity in the allo-MLR.
Dendritic cells are the most potent antigen present-
ing cells in the peripheral blood compartment, especially
when the allo-MLR is used as a T-cell proliferation as-
say. It is assumed that the allo-MLR reflects the capacity
of antigen-presenting cells to stimulate proliferation of
naive T cells [21]. Especially in vaccination procedures,
an induction of the primary immune response, that is
switching on the antigen-specific naı¨ve T cells, is the key
event that will lead to antibody production by B cells
[22]. The percentage of dendritic cells usually does not
exceed 1% to 2% of the total cell population in the pe-
ripheral blood. However, dendritic cells are at least 30-
to 100-fold more potent then monocytes as stimulators of
allogeneic T cells. Even at dendritic cells to T-cell ratios as
low as 1:900 a significant T-cell proliferation can be moni-
tored [11]. A decrease in numbers of circulating dendritic
cells after GM-CSF, as observed in this study, therefore
can explain the decrease in proliferation responses in the
allo-MLR. This was further supported by the weak, but
statistically significant correlation, between numbers of
dendritic cells/mL and proliferation of allogeneic T cells.
We were unable to find published data on the effect of
GM-CSF administration in humans, in relation to den-
dritic cells. However, one study reported an increased
number of circulating dendritic cells after prolonged and
high dose administration of GM-CSF in combination with
IL-2 [23].
A novel finding was the lower number of circulating
dendritic cells in the peripheral blood of dialysis patients
compared to healthy controls. We have now extended
this finding to patients on peritoneal dialysis and patients
with ESRD just before starting renal replacement ther-
apy (manuscript in preparation). Therefore, ESRD per
se and not the dialysis procedure, seems to cause this re-
markable decrease in circulating dendritic cells. So far
the mechanism underlying this decrease in number of
circulating dendritic cells is unknown. It may involve a
decreased generation of dendritic cells at the level of the
bone marrow, or a decreased survival in the peripheral
blood. To what extend uremic toxins might influence den-
dritic cell kinetics and function, is not known.
Two subtypes of dendritic cells have been described,
DC1 stimulating Th1 responses and DC2 stimulating Th2
responses. In hemodialysis patients a shift in Th1/Th2 ra-
tio has been described in favor of Th1, which may account
for a decreased B-cell response after vaccination [24, 25].
However, we observed a comparable decrease of 50%
in both DC1 and DC2 cell count. Despite the decreased
number of dendritic cells, the PBMC from dialysis pa-
tients and healthy controls stimulated proliferation re-
sponses of allogeneic T cells to a similar extent. Because
these assays were performed with unfractionated PBMC
it may be that other cells like monocytes have influenced
the results.
An unexpected and novel finding was the decreased
proliferation response of PBMC to recall antigens, specif-
ically tetanus toxoid, in the group of patients defined as
primary nonresponders. Based on results from previous
studies, it seems likely that this is caused by an impaired
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function of antigen-presenting cells [3, 7]. In the study by
Gibbons et al, the lowered T-cell responses of hemodial-
ysis patients to the same recall antigens could be restored
by MHC class II matched monocytes from healthy con-
trols [7]. A decreased proliferation response of PBMC
to PHA has been described before by Meuer et al [3] in
dialysis patients not responding to standard hepatitis B
vaccination. This response could also be restored by using
monocytes from healthy controls. Unlike observations by
others, we could not detect a lowered CD86 expression
on monocytes of dialysis patients compared to healthy
controls [5]. A relative deficiency of CD86 expression on
monocytes, with subsequent less co-stimulation via CD28
on T cells, is therefore not the explanation for decreased
antigen-presentation capacity in this group of dialysis pa-
tients. Monocytes have an antigen-presenting capacity
for memory T cells but dendritic cells are far more po-
tent antigen-presenting cells [26]. Therefore, an impaired
function of dendritic cells in primary nonresponders
may underlie the impaired memory T-cell proliferation
responses. In addition, the decrease in dendritic cell num-
bers after GM-CSF administration may contribute to
a further decrease in memory T-cell proliferation re-
sponses, as was observed in the majority of patients.
In the current study it was technically not feasible to
isolate peripheral blood dendritic cells, because large vol-
umes of blood are required to purify cells that circulate
at such low frequency among PBMC. Therefore, we can-
not directly document the effect of GM-CSF on dendritic
cell function, but could only show the disappearance of
these cells from the peripheral blood in conjunction with
a decrease in the proliferative responses in the antigen-
presentation assays. The monocytes could be highly pu-
rified but showed a similar efficacy as stimulator cells for
allogeneic T cells before and after administration of GM-
CSF. Again it should be emphasized that the stimulatory
capacity of monocytes in the allo-MLR is much lower
than dendritic cells [11, 21]. To our knowledge this impor-
tant finding has been neglected in all studies on antigen-
presenting cells in patients with ESRD. Even as little as
1% dendritic cells in a monocyte population may greatly
affect the results in T-cell proliferation assays.
Dendritic cells leaving the peripheral blood and enter-
ing lymphoid tissue and skin after GM-CSF administra-
tion, may be the explanation for our paradoxic finding of
increased vaccination response and decreased antigen-
presenting capacity of PBMC. The increased presence
of these pivotal antigen-presenting cells for initiating the
primary immune response will lead to the observed ad-
juvant effect of GM-CSF for hepatitis B vaccination. Di-
rect evidence for this hypothesis is lacking, and only in
mice it has been shown that GM-CSF administration in-
creases the number of splenic dendritic cells, especially
DC1 [27, 28]. In hemodialysis patients a relative paucity
of dendritic cells in the skin has been observed [29, 30].
An influx of dendritic cells from the peripheral blood af-
ter GM-CSF administration would certainly benefit the
initial phase of the immune response, that is antigen up-
take, processing and migration of antigen-loaded den-
dritic cells to the draining lymph node for presentation
tot T cells [8, 9].
Further research is needed to elucidate dendritic cell
kinetics and function in uremic patients, in relation to
GM-CSF administration and in relation to T-cell re-
sponses after vaccination.
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